Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | KMO | O15229 | 1/20 | 0.61 |
| ▸ | KDM4C | Q9H3R0 | 8/20 | 0.59 |
| ▸ | KDM5C | P41229 | 7/20 | 0.59 |
| ▸ | KDM4A | O75164 | 6/20 | 0.59 |
| ▸ | KDM2A | Q9Y2K7 | 5/20 | 0.59 |
| ▸ | KDM3A | Q9Y4C1 | 5/20 | 0.59 |
| ▸ | KDM4E | B2RXH2 | 5/20 | 0.59 |
| ▸ | KDM6B | O15054 | 4/20 | 0.59 |
| ▸ | KDM5B | Q9UGL1 | 4/20 | 0.58 |
| ▸ | KDM4B | O94953 | 3/20 | 0.58 |
| ▸ | TET3 | O43151 | 1/20 | 0.58 |
| ▸ | BBOX1 | O75936 | 1/20 | 0.58 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.58 |
| ▸ | MAPT | P10636 | 1/20 | 0.58 |
| ▸ | KDM5A | P29375 | 1/20 | 0.58 |
| ▸ | ASPH | Q12797 | 1/20 | 0.58 |
| ▸ | KDM4D | Q6B0I6 | 1/20 | 0.58 |
| ▸ | TET2 | Q6N021 | 1/20 | 0.58 |
| ▸ | ALKBH5 | Q6P6C2 | 1/20 | 0.58 |
| ▸ | KDM7A | Q6ZMT4 | 1/20 | 0.58 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL648273 | 0.87 | KDM4C (0.71) | KMOKDM4CKDM5CKDM4AKDM2A | |
| SCHEMBL29541336 | 0.87 | KDM4C (0.71) | KMOKDM4CKDM5CKDM4AKDM2A | |
| SCHEMBL30318846 | 0.86 | KMO (0.67) | KMOKDM4CKDM5CKDM4AKDM2A | |
| SCHEMBL23303939 | 0.86 | KMO (0.67) | KMOKDM4CKDM5CKDM4AKDM2A | |
| SCHEMBL3737328 | 0.85 | KDM4C (0.69) | KMOKDM4CKDM5CKDM4AKDM2A | |
| SCHEMBL70700 | 0.84 | KDM4C (0.78) | KMOKDM4CKDM5CKDM4AKDM2A | |
| SCHEMBL29407015 | 0.84 | KDM4C (0.78) | KMOKDM4CKDM5CKDM4AKDM2A | |
| SCHEMBL1592852 | 0.84 | KDM4B (0.58) | KMOKDM5CKDM4AKDM2AKDM3A | |
| SCHEMBL28270191 | 0.83 | KMO (0.68) | KMOKDM4CKDM5CKDM4AKDM2A | |
| SCHEMBL31301524 | 0.82 | KMO (0.71) | KMOKDM4CKDM5CKDM4AKDM2A |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 7 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-11174245-B2 | Benzimidazole compounds and derivatives as EGFR inhibitors | BOEHRINGER INGELHEIM INTERNATIONAL GMBH (DE) | 2021-11-16 | — | — | US | disclosed |
| US-20200377476-A1 | NEW BENZIMIDAZOLE COMPOUNDS AND DERIVATIVES AS EGFR INHIBITORS | BOEHRINGER INGELHEIM INTERNATIONAL GMBH (DE) | 2020-12-03 | — | — | US | disclosed |
| EP-2499121-B1 | OXAZOLINE DERIVATIVES FOR TREATMENT OF CNS DISORDERS. | HOFFMANN LA ROCHE (CH) | 2015-10-07 | — | — | EP | disclosed |
| US-8354441-B2 | Oxazoline derivatives | HOFFMANN-LA ROCHE INC. (US) | 2013-01-15 | — | — | US | disclosed |
| EP-2499121-A1 | OXAZOLINE DERIVATIVES FOR TREATMENT OF CNS DISORDERS. | F. Hoffmann-La Roche AG (CH) | 2012-09-19 | — | — | EP | disclosed |
| WO-2011057973-A1 | OXAZOLINE DERIVATIVES FOR TREATMENT OF CNS DISORDERS | F. HOFFMANN-LA ROCHE AG (CH) | 2011-05-19 | — | — | WO | disclosed |
| US-20110112080-A1 | OXAZOLINE DERIVATIVES | F. HOFFMANN-LA ROCHE AG (CH) | 2011-05-12 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20200377476-A1 | NEW BENZIMIDAZOLE COMPOUNDS AND DERIVATIVES AS EGFR INHIBITORS | EGFR, ERBB2, ERBB3 | KMO 4397/4885KDM4C 3076/4885KDM5C 2363/4885 |
| US-11174245-B2 | Benzimidazole compounds and derivatives as EGFR inhibitors | EGFR, ERBB2, ERBB3 | KMO 4157/4885KDM4C 2733/4885KDM5C 1735/4885 |
| US-20110112080-A1 | OXAZOLINE DERIVATIVES | TAAR1, HCRTR1, NPY1R | KMO 563/4885KDM4C 3166/4885KDM5C 3323/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.